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Introduction {#sec004}
============

Coronary artery disease (*CAD*) is still the most common cause of death in Western society. Even though the prevention and treatment of *CAD* has improved during the last three decades, the impact of sudden cardiac death (*SCD*) remains prominent\[[@pone.0203363.ref001]--[@pone.0203363.ref003]\]. The majority of *SCDs* are due to *CAD*, but to date only few clinical or biological markers have succeeded in identifying individuals at risk in an otherwise intermediate risk population of stable *CAD* patients \[[@pone.0203363.ref004]\]. The risk assessment of *SCD* in *CAD* populations has recently concentrated on markers of heart failure and impaired autonomic nervous system. In addition to left ventricular ejection fraction (*LVEF*), numerous non-invasive *ECG*-derived methodologies have been proposed to risk stratify patients for *SCD*. Among them, Holter analysis including heart rate variability and turbulence are commonly recommended for non-invasive risk stratification\[[@pone.0203363.ref005]\]. Although these markers have been shown to predict *SCD*, the majority of *SCD* victims are not identified by these measures. Feasible markers for *SCD* risk assessment in intermediate risk populations such as *CAD* patients with preserved left ventricular function are lacking. B-type natriuretic peptide (*BNP*) and high-sensitive C-reactive protein (*hs-CRP*) have provided some prognostic information in various populations, and recently, highly sensitive troponin (*hs-TnT*) and markers of cardiac fibrosis, such as *sST2* and galectin-3, have shown promising results in risk assessment of cardiovascular events in patients with *CAD* and congestive heart failure (*CHF*)\[[@pone.0203363.ref006]--[@pone.0203363.ref012]\]. The occurrence of ventricular arrhythmias is dependent on re-entry formation, and the key factors in this phenomenon are areas of slow conduction. The current hypothesis assumes that these areas are a result of accumulation of fibrosis caused by a myocardial infarction or, more commonly, by repeated episodes of transient ischemia. In many cases, this accumulation is heterogeneous in nature and does not form a stable local scar which does not conduct electricity, but an area where conduction is slow. This fibrosis accumulation is ultimately assumed to lead to reduction of systolic function, but the majority of patients develop concomitant muscle hypertrophy which delays the occurrence of pump failure. On the other hand, there is a risk for arrhythmias. The aim of the study was to test the performance of several biomarkers in risk assessment for *SCD* in *CAD* patients with preserved *LV* function. Ultimately, the goal was to find biomarkers which would coincide with the pathological pathway of fibrosis accumulation and arrhythmia risk elevation.

Methods {#sec005}
=======

The study population consisted of 1,946 patients with stable *CAD* from the *ARTEMIS* (Innovation to Reduce Cardiovascular Complications of Diabetes at the Intersection) study conducted in the Division of Cardiology of Oulu University Hospital (Oulu, Finland), ClinicalTrials.gov (Identifier NCT01426685). The goal of *ARTEMIS* study is to study the prognostic value of several traditional and novel cardiovascular risk markers in patients with stable *CAD* during a 5-year follow-up period. The design has been previously described in detail\[[@pone.0203363.ref009],[@pone.0203363.ref013]\]. The patients were recruited to a thorough risk assessment from a consecutive series of patients referred to coronary angiography in the Division of Cardiology of Oulu University Hospital (Oulu, Finland) 3 to 6 months after the angiography. Most patients had either percutaneous coronary angioplasty or coronary artery bypass during or right after the index procedure. Almost half of the patients had experienced an acute coronary event \>3 months before the enrollment into the risk profile study. Exclusion criteria were: age \<18 years or \>85 years, New York Heart Association or Canadian Cardiovascular Society class IV, significant valvular disease, permanent pacemaker or permanent or planned implantable cardioverter defibrillator implantation (*LV* ejection fraction \<35%), end-stage renal failure needing dialysis, life expectancy \<1 year. Patients who were psychologically or physically (due to any other illness) unfit for participation in the study were also excluded from this study. The study was performed according to the Declaration of Helsinki, and the local committee of research ethics of the Northern Ostrobothnia Hospital District approved the protocol, and all the subjects gave written informed consent.

Laboratory samples were obtained after 12-hour overnight fast using standardized methods. Subjects without known diabetes had an oral glucose tolerance test. *T2D*, impaired glucose tolerance, and impaired fasting glycemia were verified according to current criteria of the World Health Organization\[[@pone.0203363.ref014]\]. Patients who were on antidiabetic medication based on previous diagnosis of diabetes were also classified as having *T2D*. Blood samples and urine samples were obtained for the analysis of renal function (albumin-to-creatinine ratio), inflammation markers (*hs-CRP*), lipids, glycated hemoglobin (*HbA1c*), and cardiac markers (*BNP* and *hs-TnT*), and they were analyzed by the hospital laboratory. The concentrations of *BNP* and *hs-TnT* were determined from plasma samples (ADVIA Centaur XP, Siemens Healthcare Diagnostics and MODULAR ANALYTICS, Roche Diagnostics, respectively). The concentrations of *hs-CRP*, galectin-3, and *sST2* were determined from serum samples (BN Prospec System, Siemens Healthcare Diagnostics; Human ST2/IL-1 R4 Quantikine ELISA, R&D Systems Inc., Minneapolis, Minnesota; BG Medicine, Waltham, Massachusetts, respectively). Echocardiography was performed according to the American Society of Echocardiography guidelines. Left ventricular (*LV*) mass was calculated using the formula recommended by the American Society of Echocardiography (LV mass = 0.8 × \[1.04 {(LVIDd + PWTd + SWTd)^3^ --(LVIDd)^3^}\] + 0.6 g). *LV* mass index was calculated by dividing LV mass by body surface area. Patients with LVEF \<35% who had an indication for prophylactic implantable cardioverter-defibrillator were excluded from the consecutive series. *SYNTAX* Score was calculated by three experienced interventional cardiologists using the Web-based calculator version 2.11 on the *SYNTAX* Score Web site ([www.syntaxscore.com](http://www.syntaxscore.com/)).

The primary endpoint of the *ARTEMIS* study is *SCD*, including aborted cardiac arrests. The occurrence of *SCD* and aborted cardiac arrests was defined by an endpoint committee (*HVH* and *MJJ*) from death certificates including autopsy reports, hospital records, and contacts with next of kin. Only probable or possible sudden deaths were classified as *SCDs*, including witnessed sudden death within one hour after the onset of symptoms, or within 24 hours of when the victim was last seen alive without any evidence of non-cardiac cause of death at autopsy. The secondary endpoint of the study was defined as all-cause mortality (*ACM*).

Statistical analyses {#sec006}
--------------------

Values are expressed as mean (+/-*SD*), median (interquartile range) or the number of subjects (%). Two-tailed t-test for independent samples, Mann-Whitney U-test (if non-Gaussian distribution of the data) or chi-square were used to compare the survivors with the groups of *SCD* and *ACM*. Receiver operating characteristic (*ROC*) was used to establish the optimal cutoff value for the novel biomarkers using *SCD* as endpoint. The cutoff was set to the value that provided the maximum sum of sensitivity and specificity, sensitivity being at least 20% but less than 50% of patients having positive result. The prognostic significances of biomarkers were assessed according to the recommendations by Hlatky et al. \[[@pone.0203363.ref015]\]. These recommendations suggest that when a new risk marker is introduced in a system of multiple risk factors the ability to improve the model (which is generated with standard risk factors) should be assessed. In our study, attempts to assess the additive risk value of biomarkers have been made with C-statistics and integrated discrimination improvement (*IDI*) calculation. Hazard ratios (*HR*) with 95% confidence intervals (*CI*) were calculated by univariate Cox regression analysis for each risk marker. Thereafter, the predictive value of each biomarker was assessed in multivariate Cox regression where age, sex, body mass index, Canadian Cardiovascular Society grading of angina pectoris, left ventricular ejection fraction, albumin-creatinine ratio, estimated glomerulus filtration rate (*eGFR*), *HbA1c*, and *T2D* were entered in the model as continuous variables when applicable. The covariates were selected based on clinical significance and relevant differences found in characteristics between the groups with and without *SCD*. Multimarker Cox regression models were also established for the most significant biomarkers followed by further adjustments for potential confounders. Competing risks survival analyses were also conducted using approaches of *SCD* vs.non-sudden cardiac death.

Due to the varying follow-up time, discrimination and reclassification analyses were based on individual time-dependent estimated risk for *SCD* that was obtained by multivariate Cox regression analyses. The added discrimination of the risk markers was assessed by the C-index and the integrated discrimination index (*IDI*). Categorical and continuous net reclassification index (*NRI*; risk levels: 0--\<6, 6--\<20 and ≥20%) were also calculated\[[@pone.0203363.ref016]\]. Kaplan-Meier analysis with log rank analysis was used to describe the SCD-free survival in low- and high-risk groups. The data were analyzed using SPSS software (IBM SPSS Statistics 21, IBM Corp., New York, USA) and R Statistics (3.3.1, The R Foundation for Statistical Computing, Vienna, Austria). A p-value \<0.05 was considered statistically significant.

Results {#sec007}
=======

The characteristics of the patients are presented in [Table 1](#pone.0203363.t001){ref-type="table"}. Mean follow-up time was 76±20 months during which 205 deaths occurred of which 99 were determined to be of cardiac cause. Among cardiac deaths 50 *SCDs*, including 8 aborted cardiac arrests, were observed. Non-sudden cardiac death occurred in 44 subjects, which include pump failure and heart failure deaths. The concentrations of biomarkers, except for galectin-3, were higher in the patients who suffered *SCD* than those without the primary endpoint ([Table 1](#pone.0203363.t001){ref-type="table"}).

10.1371/journal.pone.0203363.t001

###### Characteristics of coronary artery disease patient group of survivors, sudden cardiac death (SCD) and all-cause mortality (ACM).

![](pone.0203363.t001){#pone.0203363.t001g}

                                          Survivors           SCD                                                     ACM
  --------------------------------------- ------------------- ------------------------------------------------------- -------------------------------------------------------
  Age (years)                             66 (9)              69 (7)[\*](#t001fn003){ref-type="table-fn"}             72 (8)[‡](#t001fn005){ref-type="table-fn"}
  Sex (male)                              1166 (67%)          39 (78%)                                                161 (79%)[†](#t001fn004){ref-type="table-fn"}
  BMI (kg/m^2^)                           28.3 (4.5)          28.7 (4.8)                                              28.5 (5.1)
  Systolic BP (mmHg)                      147 (24)            146 (22)                                                146 (27)
  Diastolic BP (mmHg)                     81 (11)             80 (11)                                                 79 (13)
  Smokers                                 146 (8%)            7 (14%)                                                 21 (10%)
  History of AMI (n)                      826 (48%)           28 (56%)                                                103 (50%)
  History of PCI/CABG (n)                 1386 (80%)          42 (84%)                                                158 (77%)
  Syntax score                            0 (0--5)            3 (0--8)                                                2 (0.9)[‡](#t001fn005){ref-type="table-fn"}
  CCS class (n)                                               [‡](#t001fn005){ref-type="table-fn"}                    [‡](#t001fn005){ref-type="table-fn"}
      1                                   1000 (59%)          15 (31%)                                                79 (39%)
      2                                   594 (35%)           26 (54%)                                                80 (39%)
      3                                   113 (7%)            7 (15%)                                                 41 (20%)
  Type of Glucose Metabolism Disorder                         [†](#t001fn004){ref-type="table-fn"}                    [‡](#t001fn005){ref-type="table-fn"}
      Impaired Glucose Tolerance (n)      280 (16%)           7 (14%)                                                 34 (17%)
      Impaired Fasting Glucose (n)        98 (6%)             2 (4%)                                                  5 (2%)
      Diabetes (n)                        709 (41%)           34 (68%)                                                124 (61%)
          Duration of diabetes (months)   60 (24--132)        54 (21--213)                                            96 (24--228)[†](#t001fn004){ref-type="table-fn"}
  **Medication** (n)                                                                                                  
      β-blocker                           1518 (87%)          45 (90%)                                                186 (91%)
      ACEi/ARB                            1182 (68%)          37 (74%)                                                148 (72%)
      CCB                                 422 (24%)           11 (22%)                                                52 (25%)
      Diuretics                           554 (32%)           26 (52%)[†](#t001fn004){ref-type="table-fn"}            112 (55%)[‡](#t001fn005){ref-type="table-fn"}
      Lipids                              1598 (92%)          44 (88%)                                                179 (87%)[\*](#t001fn003){ref-type="table-fn"}
  **Echogardiography**                                                                                                
      LVEF (%)                            64 (9)              58 (14)[‡](#t001fn005){ref-type="table-fn"}             61 (13)[‡](#t001fn005){ref-type="table-fn"}
      LVMI (g/m^2^)                       107 (27)            118 (30)[†](#t001fn004){ref-type="table-fn"}            118 (31)[‡](#t001fn005){ref-type="table-fn"}
      **Laboratory analyses**                                                                                         
      HbA~1c~ (%)                         6.3 (0.9)           6.9 (1.7)[‡](#t001fn005){ref-type="table-fn"}           6.8 (1.5)[‡](#t001fn005){ref-type="table-fn"}
      Total cholesterol (mmol/L)          4.0 (0.9)           4.4 (1.1)[†](#t001fn004){ref-type="table-fn"}           4.0 (1.0)
      HDL cholesterol (mmol/L)            1.3 (0.3)           1.2 (0.4)                                               1.2 (0.3)[\*](#t001fn003){ref-type="table-fn"}
      LDL cholesterol (mmol/L)            2.3 (0.8)           2.6 (1.0)[†](#t001fn004){ref-type="table-fn"}           2.3 (0.9)
      Triglycerides (mmol/L)              1.2 (0.9--1.7)      1.4 (0.9--1.9)                                          1.2 (0.9--1.7)
      eGFR (mL/min)                       95 (34)             87 (33)                                                 81 (35)[‡](#t001fn005){ref-type="table-fn"}
      U-Alb/Crea                          0.8 (0.6--1.3)      1.1 (0.9--2.4)[‡](#t001fn005){ref-type="table-fn"}      1.3 (0.7--2.6)[‡](#t001fn005){ref-type="table-fn"}
      hs-CRP (mg/L)                       0.9 (0.5--1.9)      1.8 (0.7--6.0)†                                         1.4 (0.7--3.7)[‡](#t001fn005){ref-type="table-fn"}
      hs-TnT (ng/L)                       8 (5--12)           15 (7--24)[‡](#t001fn005){ref-type="table-fn"}          15 (9--23)[‡](#t001fn005){ref-type="table-fn"}
      BNP (ng/L)                          47 (24--87)         89 (36--158)[‡](#t001fn005){ref-type="table-fn"}        91 (36--199)[‡](#t001fn005){ref-type="table-fn"}
      sST2 (ng/mL)                        16.3 (12.8--21.5)   20.3 (15.2--30.5)[‡](#t001fn005){ref-type="table-fn"}   21.5 (15.4--29.3)[‡](#t001fn005){ref-type="table-fn"}
      Galectin-3 (ng/mL)                  11.0 (9.1--13.4)    12.0 (9.0--15.6)                                        13.0 (10.4--18.6)[‡](#t001fn005){ref-type="table-fn"}

Values are means (SD), number of cases (%) or median (interquartile range).

Abbreviations: BMI = body mass index, BP = blood pressure, AMI = acute myocardial infarction, CCS = Canadian Cardiovascular Society grading of angina pectoris, ACEi = angiotensin converting enzyme, ARB = angiotensin II receptor blocker, CCB = calcium channel blocker, LVEF = left ventricle ejection fraction, LVMI = left ventricle mass index, HbA~1c~ = Glycosylated Hemoglobin, Type A1C, eGFR = estimated glomerulus filtration rate, hs-CRP = high-sensitive C-reactive protein, hs-TnT = highly sensitive Troponin T, BNP = B-type natriuretic peptide, sST2 = soluble ST2.

\* p\<0.05

† p\<0.01 and

‡ p\<0.001

Elevated *sST2* and *hs-TnT* were the most powerful predictors of the primary endpoint in the univariate analyses and also in multivariate analyses with 2.7- and 2.9-fold risk for *SCD* (p = 0.003 and p = 0.002), respectively ([Table 2](#pone.0203363.t002){ref-type="table"}). They also were the most significant risk markers in the crude and adjusted multimarker Cox regression, being significantly associated with SCD independently of *hs-CRP* and *BNP* ([Table 3](#pone.0203363.t003){ref-type="table"}). When the two most powerful biomarkers, i.e. *sST2* and *hs-TnT*, were combined, elevated concentrations in both biomarkers yielded a hazard ratio (*HR*) of 6.4 (2.6--15.5, p\<0.001) compared to those with both at normal level in multivariate Cox analysis ([Table 2](#pone.0203363.t002){ref-type="table"}). *Hs-TnT*, *hs-CRP*, *BNP* and sST2 were also significant predictors of all-cause mortality in multivariate analysis (p\<0.001 for all, [Table 2](#pone.0203363.t002){ref-type="table"}).

10.1371/journal.pone.0203363.t002

###### Univariate and multivariate Cox regression analysis of novel biomarkers as predictor of sudden cardiac death and all-cause mortality in all patients.

![](pone.0203363.t002){#pone.0203363.t002g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                        Sudden cardiac death   All-cause mortality                                                                                                                                                          
  ------------------------------------------ ---------- ---------------------- ------------------------------------------------------ ----------------------------------------------------- -------- ------------------------------------------------------ -----------------------------------------------------
  hs-TnT ≥ 15 ng/L                           404/1541   27/23                  5.0 (2.8--8.7)[‡](#t002fn005){ref-type="table-fn"}     2.9 (1.5--5.6)[†](#t002fn004){ref-type="table-fn"}    109/96   4.9 (3.7--6.4)[‡](#t002fn005){ref-type="table-fn"}     2.4 (1.7--3.3)[‡](#t002fn005){ref-type="table-fn"}

  hs-CRP ≥ 1.73 mg/L                         585/1353   24/26                  2.6 (1.5--4.5)[†](#t002fn004){ref-type="table-fn"}     2.4 (1.3--4.4)[†](#t002fn004){ref-type="table-fn"}    95/110   2.1 (1.6--2.7)[‡](#t002fn005){ref-type="table-fn"}     2.3 (1.7--3.1)[‡](#t002fn005){ref-type="table-fn"}

  BNP ≥ 88 ng/L                              536/1410   24/26                  3.2 (1.8--5.5)[‡](#t002fn005){ref-type="table-fn"}\    1.9 (1.0--3.7)[\*](#t002fn003){ref-type="table-fn"}   107/98   3.2 (2.4--4.2)[‡](#t002fn005){ref-type="table-fn"}\    1.9 (1.4--2.6)[‡](#t002fn005){ref-type="table-fn"}\

  sST2 ≥ 27.4 ng/mL                          227/1718   32/18                  4.5 (2.5--8.1)[‡](#t002fn005){ref-type="table-fn"}     2.7 (1.4--5.1)[‡](#t002fn005){ref-type="table-fn"}    63/142   3.6 (2.7--4.9)[‡](#t002fn005){ref-type="table-fn"}     2.6 (1.9--3.6)[‡](#t002fn005){ref-type="table-fn"}

  hs-TnT \< 15 ng/L and sST2 \< 27.4 ng/mL   1399/546   17/33                  Reference                                              Reference                                             76/129   Reference                                              Reference

  hs-TnT ≥ 15 ng/L and sST2 \< 27.4 ng/mL    319/1626   15/35                  4.2 (2.1--8.5)[‡](#t002fn005){ref-type="table-fn"}     2.6 (1.2--5.7)[\*](#t002fn003){ref-type="table-fn"}   66/139   4.2 (3.0--5.8)[‡](#t002fn005){ref-type="table-fn"}     2.1 (1.4--3.0)[‡](#t002fn005){ref-type="table-fn"}

  hs-TnT \< 15 ng/L and sST2 ≥ 27.4 ng/mL    142/1803   6/44                   3.6 (1.4--9.0)[†](#t002fn004){ref-type="table-fn"}     2.4 (0.9--6.8)                                        20/185   2.7 (1.6--4.4)[‡](#t002fn005){ref-type="table-fn"}     2.1 (1.3--3.5)[†](#t002fn004){ref-type="table-fn"}

  hs-TnT ≥ 15 ng/L and sST2 ≥ 27.4 ng/mL     85/1860    12/38                  13.8 (6.6--29.0)[‡](#t002fn005){ref-type="table-fn"}   6.4 (2.6--15.5)[‡](#t002fn005){ref-type="table-fn"}   43/182   11.6 (8.0--16.8)[‡](#t002fn005){ref-type="table-fn"}   5.6 (3.6--8.6)[‡](#t002fn005){ref-type="table-fn"}
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** hs-TnT = highly sensitive troponin T, sST2 = soluble ST 2

Adjusted for age, sex, body mass index, Canadian Cardiovascular Society grading of angina pectoris, left ventricular ejection fraction, estimated glomerulus filtration rate, albumin-creatinine-ratio, glycated hemoglobin, and diabetes. Seventy patients excluded due to missing covariates.

\* p\<0.05

† p\<0.01

‡ p\<0.001

10.1371/journal.pone.0203363.t003

###### Multimarker Cox regression model for the most significant biomarkers predicting sudden cardiac death and all-cause mortality.

![](pone.0203363.t003){#pone.0203363.t003g}

                       Sudden cardiac death                                  All-cause mortality                                                                                        
  -------------------- ----------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------
  hs-TnT ≥ 15 ng/L     3.2 (1.8--5.8)[‡](#t003fn005){ref-type="table-fn"}    2.4 (1.2--4.7)[\*](#t003fn003){ref-type="table-fn"}   3.3 (2.5--4.4)[‡](#t003fn005){ref-type="table-fn"}   2.0 (1.4--2.7)[‡](#t003fn005){ref-type="table-fn"}
  hs-CRP ≥ 1.73 mg/L   1.9 (1.0--3.3)[\*](#t003fn003){ref-type="table-fn"}   2.0 (1.1--3.6)[\*](#t003fn003){ref-type="table-fn"}   1.6 (1.2--2.1)[†](#t003fn004){ref-type="table-fn"}   1.8 (1.3--2.4)[‡](#t003fn005){ref-type="table-fn"}
  BNP ≥ 88 ng/L        2.1 (1.2--3.8)[\*](#t003fn003){ref-type="table-fn"}   1.7 (0.9--3.3)                                        2.2 (1.7--3.0)[‡](#t003fn005){ref-type="table-fn"}   1.7 (1.2--2.3)[†](#t003fn004){ref-type="table-fn"}
  sST2 ≥ 27.4 ng/mL    2.8 (1.5--5.2)[†](#t003fn004){ref-type="table-fn"}    2.1 (1.1--4.1)[\*](#t003fn003){ref-type="table-fn"}   2.4 (1.7--3.3)[‡](#t003fn005){ref-type="table-fn"}   2.1 (1.5--3.0)[‡](#t003fn005){ref-type="table-fn"}

**Abbreviations:** hs-TnT = highly sensitive troponin T, hs-CRP = highly sensitive C-reactive protein, BNP = B-type natriuretic peptide, sST2 = soluble ST 2

Adjusted for age, sex, body mass index, Canadian Cardiovascular Society grading of angina pectoris, left ventricular ejection fraction, estimated glomerulus filtration rate, albumin-creatinine-ratio, glycated hemoglobin, and diabetes. 70 patients excluded due to missing covariates.

\* p\<0.05

† p\<0.01

‡ p\<0.001

Elevated *hs-TnT* and *sST2* were associated with *SCD* regardless of competing risk for non-sudden cardiac death in univariate analysis (*HR*: 4.8, 95%*CI*: 2.7--8.4 for *hs-TnT* and *HR*: 3.9, 95%*CI*: 2.1--7.2 for *sST2*, p\<0.001 for both) and after adjustment for the established risk markers (*HR*: 2.8, 95%*CI*: 1.4--5.5, p = 0.003 for *hs-TnT* and *HR*: 2.5, 95%*CI*: 1.2--5.0, p = 0.012 for *sST2*). Univariate and adjusted *HR*s for the non-sudden cardiac death from the competing risks analysis were 7.5 (95%*CI*: 4.2--13.6, p\<0.001) and 2.3 (95%*CI*: 1.1--4.9, p = 0.027) for *hs-TnT*, and 4.0 (95%*CI*: 2.2--7.3, p\<0.001) and 2.7 (95%*CI*: 1.4--5.1, p = 0.003) for *sST2*, respectively.

The addition of *hs-TnT* to the established model for *SCD* improved discrimination (*IDI*: 0.012; 95% *CI*: 0.001--0.023, p = 0.035) as well as the classification by continuous (0.488; 95%*CI*: 0.204--0.772. p\<0.001) but not categorical *NRI* (0.064; 95%*CI*: -0.078--0.206, p = 0.38). The inclusion of *sST2* in the risk model did not improve discrimination (*IDI*: 0.011, 95%*CI*: -0.006--0.029. p = 0.22) and improved the classification of the patients only when analyzed by continuous *NRI* (0.349, 95%*CI*: 0.080--0.618, p = 0.011). When both elevated *hs-TnT* and *sST2* were added to the established model, C-index improved from 0.732 (95%CI: 0.665--0.799) to 0.780 (95%CI: 0.720--0.839); the *IDI* being significant (0.023; 95%CI: 0.002--0.043, p = 0.028). Continuous (0.400, 95%CI: 0.114--0.686, p = 0.006), but not categorical *NRI* (0.133; 95%CI: -0.033--0.300, p = 0.12), indicated improved classification of the cases. The Kaplan-Meier curves of elevated *hs-TnT*, *sST2*, and their combination are presented in the [Fig 1](#pone.0203363.g001){ref-type="fig"}.

![Kaplan-Meier curves of sudden cardiac death (SCD) free survival of patients with elevated levels of high sensitive troponin (hs-TnT) (panel A), soluble ST2 (sST2) (panel B), or both (panel C). + indicates elevated values and---indicates value that is not elevated when optimal cutoffs are used.](pone.0203363.g001){#pone.0203363.g001}

In *CAD* patients with *T2D*, abnormal *hs-TnT* and *hs-CRP* were the only variables that predicted *SCD* (34 events, 4.1%) in the multivariate analysis (hazard ratio: 3.0; 95%CI: 1.2--7.2, p = 0.014 and hazard ratio 2.6; 95% *CI*: 1.2--5.4, p = 0.012), whereas among those without *T2D*, only abnormal *sST2* predicted the primary outcome (16 events, 1.4%; hazard ratio: 7.2; 95%*CI*: 2.4--22.0, p = 0.001). *Hs-TnT*, *hs-CRP*, *BNP* and *sST2* were significant predictors of all-cause mortality in *CAD* patients with (2.8-, 2.8-, 1.5 and 2.6-fold adjusted risk, respectively, p\<0.05 for all) and without *T2D* (1.9-, 1.6-, 2.6 and 3.0-fold adjusted risk, respectively, p\<0.05 for all).

Discussion {#sec008}
==========

This study showed that measurement of biomarkers from blood samples provides information on *SCD* risk among the patients with *CAD* and preserved left ventricular function. Soluble *ST2* and *hs-TnT* were the most powerful predictors after adjustments with several clinical and laboratory variables as well as *LVEF*. A combination of elevated concentrations of both sST2 and hs-TnT yielded high predictive accuracy in *SCD* prediction in this population.

The present study aimed to focus on the risk assessment of *SCD* among *CAD* patients with preserved left ventricular function, since the majority of *SCD* victims have a heart disease with normal or mildly impaired cardiac function\[[@pone.0203363.ref017],[@pone.0203363.ref018]\]. Furthermore, the majority of prior risk stratification studies have focused on patients with *CHF* or on those with a recent acute myocardial infarction. This has raised the question of whether any of the risk stratification methods can be improved in order to develop appropriate preventive strategies for this large number of potential victims of *SCD* included in the present study.

Biomarkers in risk prediction {#sec009}
-----------------------------

All biomarkers included in this study have provided prognostic information in various patient populations in prior studies, but the utility of these variables in prediction of *SCD* risk has not been thoroughly studied. To our knowledge, *BNP* is the only biomarker that has been shown to predict SCD after acute myocardial infarction\[[@pone.0203363.ref019]\]. The other biomarkers, such as *sST2*, *hs-TnT*, galectin-3 and *hs-CRP*, have predicted all-cause and cardiac mortality among patients with heart failure, stable *CAD* and even in general population\[[@pone.0203363.ref006],[@pone.0203363.ref008],[@pone.0203363.ref010],[@pone.0203363.ref020],[@pone.0203363.ref021]\], but only one of these studies focused specifically on the occurrence of *SCD* in patients with *CHF* \[[@pone.0203363.ref011]\] while none focused on the occurrence of *SCD* in patients with preserved left ventricular function. Multimarker strategy, i.e. combination of two or more risk variables, has been shown to improve the prediction of cardiovascular events in previous studies\[[@pone.0203363.ref010],[@pone.0203363.ref022]\]. Combination of elevated *sST2* and *hs-TnT* in the present population also provided the most powerful information on the risk of *SCD*.

Potential mechanisms of association between sST2, hs-TnT and SCD {#sec010}
----------------------------------------------------------------

Soluble *ST2* and *hs-TnT* were the strongest predictors of *SCD* in the present study. Soluble *ST2* is a member of the interleukin-1 receptor family and circulating *sST2* concentrations are believed to reflect cardiovascular stress and cardiac fibrosis\[[@pone.0203363.ref023],[@pone.0203363.ref024]\]. Soluble *ST2* is elevated in *CHF*, older age and in diabetes\[[@pone.0203363.ref025]\]. It has also been shown that genetic factors explain up to 45% of the *sST2* concentrations in general population\[[@pone.0203363.ref026]\]. *Hs-TnT* is a novel marker reflecting ongoing myocyte death and apoptosis without any evidence of an acute ischemic event. Elevated levels of *hs-TnT* have been associated with higher risk of incident coronary event, hospitalization due to heart failure, cardiac mortality, cardiovascular mortality, stroke and cancer\[[@pone.0203363.ref006]--[@pone.0203363.ref008],[@pone.0203363.ref027],[@pone.0203363.ref028]\]. In our prior pilot study of the *ARTEMIS* population, we found that *hs-TnT* is a strong predictor of a composite endpoint of cardiac death and hospitalization for heart failure during a 2-year follow-up\[[@pone.0203363.ref009]\].

The mechanism why both *sST2* and *hs-TnT* predicted *SCD* remains speculative. These two biomarkers obviously reflect partly different aspects of cardiovascular stress and tissue damage leading to untoward cardiac events, either progressive heart failure or occurrence of *SCD* even without prior evidence of left ventricular systolic dysfunction. It can be hypothesized that elevated *hs-TnT* is a marker of ongoing myocyte loss and elevated *sST2* reflects the consequent cardiac replacement fibrosis as a result of cell death, which eventually creates a substrate for fatal arrhythmia. Fibrotic scarring has been shown to correlate strongly with an increased incidence of arrhythmias and *SCD*\[[@pone.0203363.ref029]\]. Our results thus suggest that *CAD* patients who would otherwise be at low to intermediate risk of *SCD* can be included in a higher risk group with biomarkers of inducted replacement fibrosis accumulation. This paradigm explains partly why some patients with stable *CAD* and normal *LV* function enter a downslope in prognosis through continuous cell death and formation of replacement fibrosis. This scenario would eventually end up in decreased *LV* systolic function, but we do not currently often encounter *CAD* patients with decreasing LV function. On the other hand, the number of patients with some form of heart failure with preserved *EF* is increasing. Thus more patients with accumulated fibrosis are at risk of lethal arrhythmias than lethal pump failure.

Potential limitations {#sec011}
---------------------

The *ARTEMIS* study design including a relatively large number of patients with *T2D* is a potential limitation of the present study. The power of the study does not allow risk prediction separately for non-diabetic patients. Therefore, it remains uncertain whether the present results are applicable only to *CAD* patients with *T2D* but not to non-diabetic patients. Further studies should focus also on non-diabetic patients with preserved left ventricular function. A larger sample size is needed for this purpose, since the incidence of *SCD* is much smaller in non-diabetic patients with *CAD* as compared to their diabetic counterparts\[[@pone.0203363.ref030]\]. It is clear that these results are not strong enough for interventional therapy with *ICD*, but the hypothesis of ongoing fibrosis accumulation in *CAD* patients would hopefully result in more precise examination methods and more sophisticated intervention methods in the future. Additionally, in our analysis we used low sensitivity *ELISA* assays which are not approved for clinical diagnostics and can be viewed as a potential limitation. Also the number of subjects in this study prevented us from dividing the population to training and test cohorts. Unfortunately we do not have sufficient interim information on *EF%* development in this study and thus cannot show whether the biomarker levels are specifically associated with *SCD* or deterioration of *LV* systolic function.

Conclusions {#sec012}
-----------

The present study showed that analysis of serum biomarkers can provide important information on the risk of *SCD* in *CAD* patients with preserved left ventricular systolic function. The multimarker strategy appeared very useful in this respect. Future research should focus on preventive strategies among patients with elevated levels of biomarkers, especially both *hs-TnT* and *sST2*. Examples include angiotensin-converting enzyme inhibitors, aldosterone antagonists, nesiritide, emerging antifibrotic therapies\[[@pone.0203363.ref031]\], or perhaps novel pharmacological antidiabetic strategies\[[@pone.0203363.ref032]\].
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